Key points are not available for this paper at this time.
TWELVE years ago in the Journal, Dr. F. D. Moore and his colleagues evaluated the various forms of therapy then current for the treatment of both primary and metastatic breast carcinoma.1 In 1967 most patients with breast cancer were treated initially with mastectomy, and at the time of relapse one of various endocrine treatments was employed. This is still true in the United States.2 , 3 However, there has been a plateau in the survival curves of breast-cancer patients since about 1955.4 As a result, therapeutic approaches based on new concepts of the disease, some of these approaches merely mentioned in . . .
Henderson et al. (Thu,) studied this question.